HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-density lipoprotein (HDL) cholesterol levels are a strong inverse predictor of cardiovascular events. However, it is not clear whether this association is maintained at very low levels of low-density lipoprotein (LDL) cholesterol. METHODS: A post hoc analysis of the recently completed Treating to New Targets (TNT) study assessed the predictive value of HDL cholesterol levels in 9770 patients. The primary outcome measure was the time to a first major cardiovascular event, defined as death from coronary heart disease, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. The predictive relationship between HDL cholesterol levels at the third month of treatment with statins and the time to the first major cardiovascular event was assessed in univariate and multivariate analyses and was also assessed for specific LDL cholesterol strata, including subjects with LDL cholesterol levels below 70 mg per deciliter (1.8 mmol per liter). RESULTS: The HDL cholesterol level in patients receiving statins was predictive of major cardiovascular events across the TNT study cohort, both when HDL cholesterol was considered as a continuous variable and when subjects were stratified according to quintiles of HDL cholesterol level. When the analysis was stratified according to LDL cholesterol level in patients receiving statins, the relationship between HDL cholesterol level and major cardiovascular events was of borderline significance (P=0.05). Even among study subjects with LDL cholesterol levels below 70 mg per deciliter, those in the highest quintile of HDL cholesterol level were at less risk for major cardiovascular events than those in the lowest quintile (P=0.03). CONCLUSIONS: In this post hoc analysis, HDL cholesterol levels were predictive of major cardiovascular events in patients treated with statins. This relationship was also observed among patients with LDL cholesterol levels below 70 mg per deciliter. (ClinicalTrials.gov number, NCT00327691 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies have shown that HDL cholesterol (HDL-C) levels under statin treatment remain an independent predictor of the risk of cardiovascular events in patients who have been treated with statins to lower LDL-C levels4”
From MicroRNA‐33 Deficiency Reduces the Progression of Atherosclerotic Plaque in ApoE −/− Mice (2012) · cites this paper as [4]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.151”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [151]
In the citing paper
“Despite such an effect, however, the elevated CV risk associated specifically with low HDL-C levels was only partially corrected by statin treatment in the Treatment to New Targets (TNT) trial.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [292]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
In the citing paper
“existing evidence suggests that improved HDL levels are closely associated with reduced cardiovascular risk, indicating the potential value of nurse-led DSME in preventing T2DM complications (22).”
From Impact of nurse-led self-management education on type 2 diabetes: a meta-analysis (2025) · cites this paper as [22]
Citations
Cites
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citationDowns, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationPREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- 10.1001/jama.251.3.351 · DOI · Paper page
Cited by
Items 301–400 of 1,001
Steptoe, A., & Fancourt, D. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-63600-9 · Cited by 63
High-Density Lipoprotein Functionality in Coronary Artery Disease
Kosmas, C. E., Christodoulidis, G., Cheng, J.-W., Lerakis, S., & Vittorio, T. J. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000231 · Cited by 52
Current Therapies Focused on High-Density Lipoproteins Associated with Cardiovascular Disease
Estrada-Luna, D., Ortiz-Rodríguez, M. A., Medina-Briseño, L., Carreón‐Torres, E., Vega, J. A. I., Sharma, A. K., Cancino‐Díaz, J. C., Pérez-Méndez, O. A., Belefant‐Miller, H., & Cabrera, G. B. (2018) · Molecules · doi:10.3390/molecules23112730 · Cited by 54
Pan, B., Ma, Y., Ren, H., He, Y., Wang, Y., Lv, X., Liu, D., Liang, J., Yu, B., Wang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048530 · Cited by 49
Sharma, R., Singh, V. N., & Reddy, H. K. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5684 · Cited by 59
van de Woestijne, A. P., van der Graaf, Y., Liem, A. H., Cramer, M. J., Westerink, J., & Visseren, F. L. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.101 · Cited by 47
Pitavastatin: Clinical effects from the LIVES Study
Teramoto, T. (2011) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(11)70888-1 · Cited by 48
HDL Metabolism and CETP Inhibition
Barkowski, R. S., & Frishman, W. H. (2008) · Cardiology in Review · doi:10.1097/crd.0b013e31816a3b60 · Cited by 51
Lazo-Porras, M., Bernabé‐Ortiz, A., Málaga, G., Gilman, R. H., Acuña-Villaorduña, A., Cárdenas-Montero, D., Smeeth, L. L., & Miranda, J. J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.039 · Cited by 53
Haghighian, M. K., Rafraf, M., Moghaddam, A., Hemmati, S., Jafarabadi, M. A., & Gargari, B. P. (2016) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2016.06.010 · Cited by 46
A Novel Family-Based Intervention Trial to Improve Heart Health: FIT Heart
Mosca, L. J., Greenberger, H. M., Liao, M., Christian, A. H., Edelman, D. J., Aggarwal, B., & Öz, M. C. (2008) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.825786 · Cited by 53
Niacin: The Evidence, Clinical Use, and Future Directions
Villines, T. C., Kim, A. S., Gore, R. S., & Taylor, A. J. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0212-1 · Cited by 55
Yan, L., Wang, D.-X., Liu, H., Zhang, X.-X., Zhao, H., Hua, L., Xu, P., & Li, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098368 · Cited by 47
Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease
Krychtiuk, K. A., Kastl, S., Pfaffenberger, S., Pongratz, T., Hofbauer, S. L., Wonnerth, A., Katsaros, K. M., Goliasch, G., Gašpar, Ľ., Huber, K., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.015 · Cited by 51
Ramos, D. C., Almeda‐Valdés, P., Chávez‐Manzanera, E., Meza-Arana, C. E., Brito-Córdova, G. X., Mehta, R., Pérez-Méndez, O. O., & Gomez-Perez, F. J. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s48858 · Cited by 53
Lipid control in patients with diabetes mellitus
Betteridge, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.23 · Cited by 58
“show that baseline HDL-cholesterol levels remain an important predictor of CVD in both placebo and statin-treated patients, even in the setting of intensive statin therapy, as reported in TNT”
ResultCurrent concept of reverse cholesterol transport and novel strategy for atheroprotection
Ono, K. (2012) · Journal of Cardiology · doi:10.1016/j.jjcc.2012.07.014 · Cited by 54
Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics
Salazar, J. J., Olivar, L. C., Ramos, E., Chávez-Castillo, M., Rojas, J., & Bermúdez, V. (2015) · Cholesterol · doi:10.1155/2015/296417 · Cited by 55
Vitamin D Deficiency Prevalence and Predictors in Early Pregnancy among Arab Women
Al-Musharaf, S., Fouda, M. A., Turkestani, I. Z., Al-Ajlan, A., Sabico, S., Alnaami, A. M., Wani, K., Hussain, S. D., Alraqebah, B. A., Al-Serehi, A., et al. (2018) · Nutrients · doi:10.3390/nu10040489 · Cited by 52
Basit, A., Sabir, S., Riaz, M., Fawwad, A., members, N., Abro, M. U. R., Ahmed, K. I., Ahmed, K., Bilal, A., Butt, A., et al. (2020) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-020-00631-z · Cited by 46
Acne patients frequently associated with abnormal plasma lipid profile
Hao, J., Li, C. Y., Zhou, L., Lu, B., Lin, Y., Huang, X., Wei, B., Wang, Q., Wang, L., & Lu, J. (2015) · The Journal of Dermatology · doi:10.1111/1346-8138.12761 · Cited by 52
Experimental Models for the Investigation of High-Density Lipoprotein–Mediated Cholesterol Efflux
Santos‐Gallego, C. G., Giannarelli, C., & Badimón, J. J. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0177-0 · Cited by 55
“O sa ka S tu dy [5 1] 64 08 ur ba n Ja pa ne se m al e w or ke rs , ag ed”
BackgroundMethodInfluentialSibley, C. T., Vavere, A. L., Gottlieb, I., Cox, C., Matheson, M. B., Spooner, A. E., Godoy, G., Fernandes, V., Wasserman, B. A., Bluemke, D. A., et al. (2013) · Heart · doi:10.1136/heartjnl-2013-303926 · Cited by 47
Glycemia, Diabetes Status, and Cognition in Hispanic Adults Aged 55–64 Years
Luchsinger, J. A., Cabral, R., Eimicke, J. P., Manly, J. J., & Teresi, J. A. (2015) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000208 · Cited by 48
Effects of Orthodox religious fasting on human health: a systematic review
Koufakis, T., Karras, S. Ν., Antonopoulou, V., Angeloudi, E., Zebekakis, P. E., & Kotsa, K. (2017) · European Journal of Nutrition · doi:10.1007/s00394-017-1534-8 · Cited by 46
Chan, D. C., Ng, T. W., & Watts, G. F. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.573498 · Cited by 57
Rationale for cholesteryl ester transfer protein inhibition
Hewing, B., & Fisher, E. A. A. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328353ef1d · Cited by 46
The Present and Future of Lipid Testing in Cardiovascular Risk Assessment
Habeeb, N. W.-A., Higgins, V., Wolska, A. T., Delaney, S. R., Remaley, A. T., & Beriault, D. R. (2023) · Clinical Chemistry · doi:10.1093/clinchem/hvad012 · Cited by 51
Marra, A., Bondesan, A., Caroli, D., & Sartório, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051353 · Cited by 55
“However, in individuals with low HDL-C levels, this protective effect is diminished, thus leading to an increase in inflammation and atherosclerosis [19].”
BackgroundLipoproteins as Biomarkers and Therapeutic Targets in the Setting of Acute Coronary Syndrome
Rosenson, R. S., Brewer, H. B., & Rader, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.302805 · Cited by 52
Sharif, S., van der Graaf, Y., Nathoe, H. M., de Valk, H. W., Visseren, F. L. J., Westerink, J., & on behalf of the SMART Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0155 · Cited by 48
Olvera, R. L., Williamson, D. E., Fisher‐Hoch, S. P., Vatcheva, K. P., & McCormick, J. B. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09118 · Cited by 58
Kang, H., Yoon, J., Kim, J.-Y., Ahn, S., Linton, J. A., Koh, S. B., & Kim, J. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.01.013 · Cited by 51
Pharmacotherapies for lipid modification: beyond the statins
Gotto, A. M., & Moon, J. E. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.117 · Cited by 46
Self-citationOboh, G., Bello, F. O., Ademosun, A. O., Akinyemi, A. J., & Adewuni, T. M. (2015) · Comparative Clinical Pathology · doi:10.1007/s00580-015-2088-x · Cited by 49
“Low HDL-cholesterol levels are seen as the most important criteria for predicting the likelihood of future cardiovascular disease occurrence (Barter et al. 2007).”
BackgroundGe, P., Dong, C., Ren, X., Weiderpass, E., Zhang, C., Fan, H., Zhang, J., Zhang, Y., & Xi, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144104 · Cited by 44
Rosenson, R. S. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307024 · Cited by 45
Ursolic acid alleviates hypercholesterolemia and modulates the gut microbiota in hamsters
Hao, W., Kwek, E., He, Z., Zhu, H., Liu, J., Zhao, Y., Ma, K. Y., He, W., & Chen, Z. (2020) · Food & Function · doi:10.1039/d0fo00829j · Cited by 46
Prats‐Uribe, A., Sayols-Baixeras, S., Fernández‐Sanlés, A., Subirana, I., Carreras‐Torres, R., Vilahur, G., Civeira, F., Marrugat, J., Fitó, M., Hernáez, Á., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154351 · Cited by 48
“The inverse association between high-density lipoprotein cholesterol (HDL-C) levels and the risk of coronary artery disease (CAD) has been reported in observational studies [1].”
BackgroundFruchart, J. C., Sacks, F. M., Hermans, M. P., & on behalf of the International Steering Committee of Ri (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.489341 · Cited by 44
Self-citationUraemic dyslipidaemia revisited: role of high-density lipoprotein
Speer, T., Zewinger, S., & Fliser, D. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft080 · Cited by 47
Penno, G., Solini, A., Zoppini, G., Fondelli, C., Trevisan, R., Vedovato, M., Gruden, G., Lamacchia, O., Pontiroli, A. E., Arosio, M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125512 · Cited by 43
Tonkin, A. M., & Chen, L. (2010) · Circulation · doi:10.1161/circulationaha.110.960112 · Cited by 44
Santos, R. D., Waters, D. D., Tarasenko, L. C., Messig, M., Jukema, J. W., Ferrières, J., Verdejo, J., & Chiang, C.-W. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.08.009 · Cited by 46
Serum Lipids, Apolipoproteins, and Mortality among Coronary Artery Disease Patients
Ding, D., Li, X., Qiu, J., Li, R., Zhang, Y., Su, D., Li, Z., Wang, M., Lv, X., Wang, D., et al. (2014) · BioMed Research International · doi:10.1155/2014/709756 · Cited by 44
Padilla, N., Maraninchi, M., Béliard, S., Berthet, B., Nogueira, J.-P., Wolff, E., Nicolay, A., Bégu, A., Dubois, N., Grangeot, R., et al. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303849 · Cited by 43
Profiling of plasma metabolites in postmenopausal women with metabolic syndrome
Iida, M., Harada, S., Kurihara, A., Fukai, K., Kuwabara, K., Sugiyama, D., Takeuchi, A., Okamura, T., Akiyama, M. O., Nishiwaki, Y., et al. (2016) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000630 · Cited by 48
Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?
Ruscica, M., Ferri, N., Macchi, C., Corsini, A., & Sirtori, C. R. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1498118 · Cited by 47
“CETP inhibitor Torcetrapib (187) ILLUMINATE 1.”
BackgroundInfluentialKukharchuk, V. V., Владиславович, Е. М., Викторович, С. И., Arabidze, G. G., Балахонова, Т. В., Gurevich, V. S., Zelveyan, P. A., Murataliev, T. M., Myrzakhmetova, G., Александровна, С. О., et al. (2020) · Eurasian heart journal · doi:10.38109/2225-1685-2020-2-6-29 · Cited by 51
Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos?
Badimón, J. J., Santos‐Gallego, C. G., & Badimón, L. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70150-0 · Cited by 58
Jacobson, T. A. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0128 · Cited by 49
Goldenberg, I., Boyko, V., Tennenbaum, A., Tanne, D., Behar, S., & Guetta, V. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.584 · Cited by 42
“2 NYHA class II 360 (24) 246 (25) 125 (26) AP class II 880 (58) 562 (55) 292 (59) COPD 51 (3) 25 (3) 10 (2) PVD 54 (4) 32 (3) 18 (4) SBP, mm Hg, mean ± SD 133 ± 18 134 ± 18 134 ± 19 DBP, mm Hg, mean ± SD 81 ± 9 81 ± 9 81 ± 9 Metabolic syndromec 479 (32) 312 (31) 158 (32) Nonstudy LLDs 270 (18) 110 (11) 50 (10) Lipid l…”
eNOS Activation by HDL Is Impaired in Genetic CETP Deficiency
Gomaraschi, M., Ossoli, A., Pozzi, S., Nilsson, P., Cefalu, A. B., Averna, M. R., Kuivenhoven, J. A., Hovingh, G. K., Veglia, F., Franceschini, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095925 · Cited by 42
Wang, C., Li, Y., Wang, L., Li, L., Guo, Y., Zhang, L., Zhang, M., & Bie, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043834 · Cited by 45
RetractedCordero, A., Arribas, J. M., Bertomeu‐González, V., Agudo, P., Miralles, B., Masiá, M. D., López‐Palop, R., & Bertoméu, V. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.07.022 · Cited by 43
Drexel, H., Aczél, S., Marte, T., Vonbank, A., & Saely, C. H. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.08.026 · Cited by 44
Kurogi, K., Sugiyama, S., Sakamoto, K., Tayama, S., Nakamura, S., Biwa, T., Matsui, K., & Ogawa, H. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.03.008 · Cited by 42
“[5] Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC, Treating to New Targets Investigators.”
BackgroundMethodInfluentialComparison of Preventive Effect on Cardiovascular Events With Different Statins - The CIRCLE Study -
Maruyama, T., Takada, M., Nishibori, Y., Fujita, K., Miki, K., Masuda, S., Horimatsu, T., & Hasuike, T. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1163 · Cited by 42
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I. M., Backer, G. D., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0157 · Cited by 62
Effects of Astaxanthin on Reverse Cholesterol Transport and Atherosclerosis in Mice
Zou, T., Zhu, S., Luo, F., Li, W.-Q., Sun, X., & Wu, H. (2017) · BioMed Research International · doi:10.1155/2017/4625932 · Cited by 42
The pleiotropic vasoprotective functions of high density lipoproteins (HDL)
Guilaine, B., Emily, B., Sonja, S., & Cheryl, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160103 · Cited by 41
Enani, S. M., Bahijri, S., Malibary, M., Jambi, H., Eldakhakhny, B. M., Al-Ahmadi, J., Al-Raddadi, R. M., Ajabnoor, G., Boraie, A., & Tuomilehto, J. O. (2020) · Nutrients · doi:10.3390/nu12082441 · Cited by 54
“Indeed, dyslipidemia, defined as any abnormalities in serum lipids is considered atherogenic, and is reported to be associated with an increased risk of ischemic heart disease [7,8].”
Abnormal Neurovascular Control in Anabolic Androgenic Steroids Users
Alves, M. J. D. N. N., dos Santos, M. R., Dias, R. G., AKIHO, C. A., Laterza, M. C., Rondon, M. U. P. B., Moreau, R. L. D. M., & Negrão, C. E. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181c07b74 · Cited by 46
A 90 day chronic toxicity study of Nigerian herbal preparation DAS-77 in rats
Afolabi, S. O., Akindele, A. J., Awodele, O., Anunobi, C. C., & Adeyemi, O. O. (2012) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-12-79 · Cited by 42
Hirata, H., Takazumi, K., Segawa, S., Okada, Y., Kobayashi, N., Shigyo, T., & Chiba, H. (2012) · Food Chemistry · doi:10.1016/j.foodchem.2012.03.043 · Cited by 48
The epidemiological concept of residual risk
Vanuzzo, D. (2011) · Internal and Emergency Medicine · doi:10.1007/s11739-011-0669-5 · Cited by 41
The HDL lipidome is widely remodeled by fast food versus Mediterranean diet in 4 days
Zhu, C., Sawrey-Kubicek, L., Beals, E., Hughes, R. L., Rhodes, C. H., Sacchi, R., & Zivkovic, A. M. (2019) · Metabolomics · doi:10.1007/s11306-019-1579-1 · Cited by 40
ST elevation acute myocardial infarction accelerates non-culprit coronary lesion atherosclerosis
Han, Y., Jing, J., Tu, S., Tian, F., Xue, H., Chen, W., Chen, J., Reiber, J. H. C., & Chen, Y. (2014) · International journal of cardiac imaging · doi:10.1007/s10554-013-0354-z · Cited by 44
Yang, C., Chen, Z., Wong, S. L., Liu, J., Liang, Y. T., Lau, C. W., Lee, H. K., Huang, Y., & Tsang, S. Y. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs370 · Cited by 45
Wong, N. D., Chuang, J., Wong, K., Pham, A. H., Neff, D., & Marrett, E. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.03.041 · Cited by 42
Goldenberg, I., Benderly, M., Sidi, R., Boyko, V., Tenenbaum, A., Tanné, D., & Behar, S. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.08.033 · Cited by 43
Gilde, A. J., Fruchart, J., & Staels, B. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.097 · Cited by 49
Self-citationRubenfire, M., Brook, R. D., & Rosenson, R. S. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.03.024 · Cited by 40
das Neves, M. F., Batuca, J. R., & Alves, J. D. (2021) · Immunology · doi:10.1111/imm.13348 · Cited by 42
Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus
Salvadó, L., Serrano, L., Barroso, E., Palomer, X., & Vázquez‐Carrera, M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.658370 · Cited by 48
Oh, S., Lee, M.-S., Jung, S., Kim, S., Park, H.-Y., Park, S., Kim, S.-Y., Kim, C., Jo, Y.-H., Kim, I.-H., et al. (2016) · Journal of Functional Foods · doi:10.1016/j.jff.2016.12.023 · Cited by 44
Karras, S. N., Koufakis, T., Adamidou, L., Antonopoulou, V., Karalazou, P., Thisiadou, K., Mitrofanova, E., Mulrooney, H., Petróczi, A., Zebekakis, P., et al. (2021) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2020.1760218 · Cited by 40
“It is well established that HDL-C levels present an adverse association with CV risk and that this relationship remains significant even for individuals with very low LDLC concentrations (< 70 mg/dl), as those treated with statins (Barter et al. 2007).”
BackgroundKirrella, A. A. K., Abdo, S. E., El‐Naggar, K., Soliman, M. M., Aboelenin, S. M., Dawood, M. A. O., & Saleh, A. A. (2021) · Animals · doi:10.3390/ani11041170 · Cited by 51
Reheated Palm Oil Consumption and Risk of Atherosclerosis: Evidence at Ultrastructural Level
Xian, T. K., Omar, N. A., Ying, L. W., Hamzah, A., Raj, S., Jaarin, K., Othman, F. B., & Hussan, F. (2012) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2012/828170 · Cited by 43
Cardiorespiratory Fitness, LDL Cholesterol, and CHD Mortality in Men
FARRELL, S. W., FINLEY, C. E., & GRUNDY, S. M. (2012) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31826524be · Cited by 39
Self-citationDalcetrapib: a review of Phase II data
Robinson, J. G. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.488219 · Cited by 38
Metabolic syndrome in children and adolescents with phenylketonuria
Kanufre, V. D. C., Soares, R. D. L., Alves, M. R. A., de Aguiar, M. J. B., Starling, A. L. P., & Norton, R. D. C. (2014) · Jornal de Pediatria · doi:10.1016/j.jped.2014.06.006 · Cited by 39
Derosa, G., Maffioli, P., SALVADEO, S. A. T., Ferrari, I., Gravina, A., Mereu, R., Palumbo, I., D’Angelo, A., & Cicero, A. F. G. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903073159 · Cited by 39
Cordero, A., Arribas, J. M., Bertomeu‐González, V., Agudo, P., Miralles, B., Masiá, M. D., López‐Palop, R., & Bertoméu, V. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.09.003 · Cited by 40
Apolipoprotein A-I Protects Against Pregnancy-Induced Insulin Resistance in Rats
Wu, B. J., Sun, Y., Ong, K. L., Li, Y., Tang, S., Barter, P. J., & Rye, K. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312282 · Cited by 40
Self-citationLymphatic system identification, pathophysiology and therapy in the cardiovascular diseases
Hu, D. M., Li, L., Li, S., Wu, M., Ge, N., Cui, Y., Lian, Z., Song, J., & Chen, H. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.06.002 · Cited by 47
Stoekenbroek, R. M., Stroes, E. S. G., & Hovingh, G. K. (2014) · Handbook of experimental pharmacology · doi:10.1007/978-3-319-09665-0_21 · Cited by 39
Update on the use of fibrates: focus on bezafibrate
Goldenberg, I., Benderly, M., & Goldbourt, U. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.2008.04.01.131 · Cited by 107
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients
Nicholls, S. J., Nelson, A. J., Ray, K. K., Ballantyne, C. M., Ditmarsch, M., Kling, D. F., Hsieh, A., Szarek, M. J., Kastelein, J. J. P., & Davidson, M. H. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.056 · Cited by 44
Self-citationAzmi, M. B., & Qureshi, S. A. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/376429 · Cited by 38
Tamada, M., Makita, S., Abiko, A., Naganuma, Y., Nagai, M., & Nakamura, M. (2009) · Metabolism · doi:10.1016/j.metabol.2009.09.009 · Cited by 38
Halcox, J., & Misra, A. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0049 · Cited by 45
Do, D. N., Schenkel, F. S., Miglior, F., Zhao, X., & Ibeagha-Awemu, E. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-31427-0 · Cited by 45
Gibson, C. M., Kernéis, M., Yee, M. K., Daaboul, Y., Korjian, S., Mehr, A. P., Tricoci, P., Alexander, J. H., Kastelein, J. J. P., Mehran, R., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.11.008 · Cited by 39
Self-citationDaimiel, L., Vargas, T., & de Molina, A. R. (2012) · Electrophoresis · doi:10.1002/elps.201200084 · Cited by 48
Witting, P. K., Song, C., Hsu, K., Hua, S., Parry, S. N., Aran, R., Geczy, C. L., & Freedman, S. B. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.031 · Cited by 44
Mantlo, N. B., & Escribano, A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400574e · Cited by 37
Mohseni, M., Vafa, M. R., Hajimiresmail, S. J., Zarrati, M., Rahimi Forushani, A., Bitarafan, V., & Shidfar, F. (2014) · Iranian Red Crescent Medical Journal · doi:10.5812/ircmj.16433 · Cited by 37
Recent clinical trials evaluating benefit of drug therapy for modification of HDL cholesterol
Wright, R. S. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e328362059d · Cited by 37
“There has been intense interest in developing therapies which raise HDL-C to see whether further cardiovascular risk reduction can be accomplished in patients who are on statin therapy with appropriately treated LDL-C values [5,12].”
BackgroundWu, J., He, Z., Gao, X., Wu, F., Ding, R., Ren, Y., Jiang, Q., Fan, M., Liang, C., & Wu, Z. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5743 · Cited by 38
Metadata
- Authors
- Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C.
- Affiliations
- The Heart Research Institute (AU)
- Cornell University (US)
- SUNY Downstate Health Sciences University (US)
- Pfizer (United States) (US)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Alabama (US)
- Institut Pasteur de Lille (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-27
- Volume
- 357
- Issue
- 13
- Pages
- 1301-1310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158057499
- Cited by
- 1,610
- References
- 24
- Citations by year
- 2026: 29 · 2025: 51 · 2024: 34 · 2023: 48 · 2022: 36 · 2021: 51 · 2020: 79 · 2019: 72 · 2018: 59 · 2017: 75 · 2016: 90 · 2015: 106 · 2014: 128 · 2013: 126 · 2012: 130
- FWCI
- 113.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- HDL cholesterol, LDL cholesterol, very low LDL cholesterol, major cardiovascular events, statin therapy, cardiovascular risk prediction, coronary artery disease, myocardial infarction, stroke, low HDL cholesterol
- MeSH terms
- Atorvastatin, Adult, Aged, Anticholesteremic Agents, Apolipoproteins, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Heptanoic Acids, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Pyrroles, Risk, Multivariate Analysis, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.